Thrombin JMI

PreclinicalSmall molecule

UUniversity of Kansas Medical Center

Thrombin JMI is one of 10 small molecule programs targeting Epistaxis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EpistaxisActive, not recruiting

EpistaxisPreclinical

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Epistaxis

#DrugCompanyPhaseTrials

Cyklokapron

AAmring

Approved

5 2

Avastin

BBio-Thera Solutions

Approved

1 3

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Bactroban

PPadagis LLC

Approved

—5

Adrenaline

SSamson Clinical Operations Pty Ltd

Phase 2

1 6

Rhofade

KKenvue Brands

Phase 2

1 7

Silver Nitrate

MMansoura University Hospital

Preclinical

1 8

Floseal

UUnity Health Toronto

Preclinical

2 9

Trichloroacetic Acid

IIndonesia University

Preclinical

1 10

Thrombin JMI

UUniversity of Kansas Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Tranexamic Acid

NCT06379724

Clinical

Trials by Indication[1]

Tranexamic Acid1 trial

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft

Recruiting·UUniversity of Kansas Medical Center·Phase 4·NCT06379724·62 enrolled

Epistaxis1 trial

Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis

Terminated·UUniversity of Kansas Medical Center·N/A·NCT00814333·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Thrombin JMI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thrombin JMI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thrombin JMI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Kansas Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Kansas Medical Center

Thrombin JMI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Tranexamic Acid1 trial

Epistaxis1 trial

References

Drug Info

Quick Facts

Related News